Largest pharmaceuticals by total debt
Borrowings at the end of the latest fiscal year: long-term debt including the part due within a year, plus short-term borrowings. Leases are left out unless the company reports them in one figure with its debt.
AbbVie leads the 35 pharmaceuticals ranked by total debt, at CZK 1.5T, ahead of Pfizer (CZK 1.44T) and Merck & Co (CZK 1.1T). Figures as of 18 Nov 2026, 14:23 UTC, from Yahoo Finance quotes.
Key facts
- Companies ranked
- 35
- First
- AbbVieCZK 1.5T
- Median
- CZK 117.2B
- Combined market value
- CZK 114.6T
- Countries
- 10
- Not ranked
- 26no total debt on file
Market values as of .
All countries▾
All sectors▾
Pharmaceuticals▾
| # | Company | Total debt ↓ | Market cap | Price | Today | 1 year | Price, 30 days | Country |
|---|---|---|---|---|---|---|---|---|
| 1 | AbbVieABBV · Health Care | CZK 1.5T | CZK 11.5T | CZK 6,505.58 | 0.59% down | 26% up | ||
| 2 | PfizerPFE · Health Care | CZK 1.44T | CZK 3.61T | CZK 632.52 | 1.35% down | 14% up | ||
| 3 | Merck & CoMRK · Health Care | CZK 1.1T | CZK 7.85T | CZK 3,185.25 | 0.75% down | 51% up | ||
| 4 | Johnson & JohnsonJNJ · Health Care | CZK 1.07T | CZK 14.91T | CZK 6,191.88 | 1.36% down | 38% up | ||
| 5 | Bristol-Myers SquibbBMY · Health Care | CZK 1T | CZK 2.79T | CZK 1,363.01 | 2.51% down | 34% up | ||
| 6 | Eli LillyLLY · Health Care | CZK 944.3B | CZK 28.01T | CZK 31,449.27 | 1.13% down | 35% up | ||
| 7 | Takeda PharmaceuticalTAK · Health Care | CZK 679.3B | CZK 1.54T | CZK 480.78 | 0.23% up | 54% up | ||
| 8 | AstraZenecaAZN · Health Care | CZK 658.1B | CZK 6.28T | CZK 4,049.49 | 0.95% down | 2% up | ||
| 9 | NovartisNVS · Health Care | CZK 638.3B | CZK 6.68T | CZK 3,535.39 | 0.67% down | 25% up | ||
| 10 | SanofiSNY · Health Care | CZK 461B | CZK 2.54T | CZK 1,055.97 | 1.78% down | 4% down | ||
| 11 | Novo NordiskNVO · Health Care | CZK 431.8B | CZK 3.99T | CZK 904.23 | 2.16% down | 17% down | ||
| 12 | GSKGSK · Health Care | CZK 426.2B | CZK 2.19T | CZK 1,093.97 | 2.32% down | 6% up | ||
| 13 | ViatrisVTRS · Health Care | CZK 320.2B | CZK 520.9B | CZK 454.34 | 1.40% down | 96% up | ||
| 14 | Abbott LaboratoriesABT · Health Care | CZK 287.2B | CZK 4.03T | CZK 2,326.34 | 2.55% down | 17% down | ||
| 15 | ZoetisZTS · Health Care | CZK 200.9B | CZK 753.6B | CZK 1,854.68 | 1.08% down | 29% down | ||
| 16 | Royalty PharmaRPRX · Health Care | CZK 198.9B | CZK 877.4B | CZK 1,525.86 | 0.23% up | 78% up | ||
| 17 | Jazz PharmaceuticalsJAZZ · Health Care | CZK 119B | CZK 343.3B | CZK 5,347.85 | 0.39% up | 37% up | ||
| 18 | GenmabGMAB · Health Care | CZK 117.2B | CZK 711.8B | CZK 1,154.40 | 0.76% up | 70% up | ||
| 19 | Elanco Animal HealthELAN · Health Care | CZK 89.2B | CZK 287.1B | CZK 574.31 | 2.12% down | 20% up | ||
| 20 | Amneal PharmaceuticalsAMRX · Health Care | CZK 57.1B | CZK 163.5B | CZK 469.22 | 0.52% down | 83% up | ||
| 21 | BridgeBio PharmaBBIO · Health Care | CZK 44.6B | CZK 332.4B | CZK 1,706.27 | 0.72% down | 17% up | ||
| 22 | Regeneron PharmaceuticalsREGN · Health Care | CZK 44.1B | CZK 2.2T | CZK 21,278.55 | 0.56% up | 36% up | ||
| 23 | Ionis PharmaceuticalsIONS · Health Care | CZK 40.3B | CZK 99.8B | CZK 598.97 | 3.75% down | 64% down | ||
| 24 | BeOne MedicinesONC · Health Care | CZK 22.8B | CZK 1.05T | CZK 9,181.40 | 0.48% up | 17% up | ||
| 25 | Ascendis PharmaASND · Health Care | CZK 17.8B | CZK 395.2B | CZK 6,025.03 | 0.20% down | 28% up | ||
| 26 | InsmedINSM · Health Care | CZK 12.1B | CZK 593.9B | CZK 2,707.36 | 0.83% down | 40% down | ||
| 27 | Madrigal PharmaceuticalsMDGL · Health Care | CZK 7.6B | CZK 217.8B | CZK 9,375.35 | 0.46% down | 24% down | ||
| 28 | Legend BiotechLEGN · Health Care | CZK 7.1B | CZK 69.4B | CZK 357.92 | 0.75% up | 42% down | ||
| 29 | CytokineticsCYTK · Health Care | CZK 6.4B | CZK 159.9B | CZK 1,147.51 | 2.86% down | 20% down | ||
| 30 | TG TherapeuticsTGTX · Health Care | CZK 5.5B | CZK 210.6B | CZK 1,393.23 | 0.08% down | 107% up | ||
| 31 | Cogent BiosciencesCOGT · Health Care | CZK 5B | CZK 107.7B | CZK 618.74 | 1.49% up | 20% down | ||
| 32 | Dr. Reddy's LaboratoriesRDY · Health Care | CZK 4.3B | CZK 273.9B | CZK 328.59 | 0.61% up | 5% up | ||
| 33 | Axsome TherapeuticsAXSM · Health Care | CZK 4.2B | CZK 158.9B | CZK 3,020.40 | 0.77% down | 7% down | ||
| 34 | Rhythm PharmaceuticalsRYTM · Health Care | CZK 2.4B | CZK 179.6B | CZK 2,590.72 | 8.49% up | 13% up | ||
| 35 | Definium TherapeuticsDFTX · Health Care | CZK 901.5M | CZK 89.4B | CZK 652.74 | 2.59% down | 169% up |
Sources: share prices and market values from Yahoo Finance; sector, country and category from each company's SEC registration; annual figures from the reports companies file with the SEC.
Market value is share price × shares outstanding, from Yahoo Finance; prices may be delayed 15 minutes or more and the ranking refreshes about every 20 minutes. The list covers companies with shares listed in the US, which includes foreign companies listed through ADRs but not ones listed only abroad. Sector, category and country come from each company's SEC registration. Total debt is from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day, not of the period. Total debt is assembled from each company's debt lines and is the least complete of these figures: some companies tag part of their borrowings in ways it misses. Sums are converted from US dollars at today's exchange rate (1 USD = 22.2170 CZK). 26 companies have no total debt on file and are not ranked here.
Questions and answers
Which pharmaceuticals rank first by total debt?
AbbVie (CZK 1.5T), Pfizer (CZK 1.44T) and Merck & Co (CZK 1.1T) are the top three of the 35 pharmaceuticals ranked by total debt as of 18 Nov 2026, 14:23 UTC.
How many pharmaceuticals are in this ranking?
35 are ranked by total debt. 26 more have no total debt on file and are left out rather than ranked at zero.
What are these pharmaceuticals worth together?
The 35 pharmaceuticals ranked by total debt have a combined market value of CZK 114.6T as of 18 Nov 2026, 14:23 UTC.
What does ranking by total debt measure?
Borrowings at the end of the latest fiscal year: long-term debt including the part due within a year, plus short-term borrowings. Leases are left out unless the company reports them in one figure with its debt.
Learn how this ranking works
All markets guides →- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Market cap vs enterprise value: what is the difference?
Market capitalization is the value of a company's shares. Enterprise value is market cap plus debt, minus cash: roughly what it would cost to buy the whole business and settle its borrowings. Two companies with the same $50 billion market cap can have very different enterprise values if one owes $20 billion and the other holds $20 billion in cash.
- How an ETF's size is measured: AUM, NAV and creation units
An ETF's size is usually measured by its assets under management (AUM), the fund's net assets: everything it holds minus what it owes. That equals net asset value per share times shares outstanding. AUM grows when the holdings rise in value and when large institutions create new shares, and shrinks when they redeem them.
Cite this page
Funkfolio, “Largest pharmaceuticals by total debt”, data as of 18 November 2026. https://funkfolio.com/companies/category/pharmaceuticals?by=total-debt
Underlying data: Yahoo Finance; SEC EDGAR.